A Registry: Siltartoxatug Injection for Tetanus Prophylaxis Following Injury

Not yet recruitingOBSERVATIONAL
Enrollment

10,000

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

March 30, 2029

Study Completion Date

March 30, 2029

Conditions
Tetanus
Interventions
DRUG

Siltartoxatug Injection (Brand name: Sintetol®)

The injury and wound conditions of the enrolled patients will be documented. A follow-up at 90 days post-administration will determine the clinical outcome of tetanus prophylaxis, specifically whether tetanus occurred. The registry will also employ selective safety data collection to record adverse reactions and serious adverse events following Siltartoxatug adminstration.

Trial Locations (4)

312030

Shaoxing Central Hospital, Shaoxing

316100

Zhoushan Putuo District People's Hospital, Zhoushan

515041

The Second Affiliated Hospital of Shantou University, Shantou

672100

Xiangyun County People's Hospital, Xiangyun

All Listed Sponsors
lead

Zhuhai Trinomab Pharmaceutical Co., Ltd.

INDUSTRY

NCT07107932 - A Registry: Siltartoxatug Injection for Tetanus Prophylaxis Following Injury | Biotech Hunter | Biotech Hunter